The Company is authorized to issue an unlimited number of voting common shares and non-voting common shares, each without par value. At June 30, 2026, 54,069,407 voting common shares and 2,312,243 non-voting common shares were issued and outstanding, for a total of 56,381,650 common shares.

Share capital increased by $10,798,100 during the three months ended June 30, 2026 and by $27,632,943 during the nine months ended June 30, 2026. The three-month movements reflected 898,280 restricted share units settled under FAR Holdings arrangements; exercises of 745,606 stock options; exercises of 745,606 JGB First Warrants on a cashless basis; conversion of $600,000 of JGB principal into 150,000 common shares; conversion of $125,000 of October 2025 note principal, together with accrued interest, into 34,410 common shares; and related fair-value transfers to share capital.

Contributed surplus increased by $3,116,049 during the three months ended June 30, 2026 and by $3,927,216 during the nine months ended June 30, 2026, reflecting share-based compensation expense, reclassifications on exercises and settlements and other equity-award movements.

The following tables reconcile common shares, stock options, restricted share units and warrants. Three-month opening balances are at March 31, 2026 and nine-month opening balances are at September 30, 2025.

At June 30, 2026, the exercise prices of outstanding and exercisable options ranged from $4.00 to $5.55 per share, the weighted-average exercise price was $4.48 per share and the weighted-average remaining contractual life was 1.50 years.

The 425,000 restricted share units granted on June 22, 2026 were vested at June 30, 2026 and settled in common shares on July 6, 2026.